I would not call it gambling, really. Yes, investors need to do their full research and make decision that suit their appetite.
The fall in Ebita was clearly explained by delay in a project and additional spending for strategic development, obviously it was for Cognigram, with improved deployment model in general practice medicine, opening a new market.
Will Cognigram be a success? Cognigram received FDA clearance at the end of Jul. Its first commercial in USA is announced in early Oct, an impressive confirmation of CGS reputation in the field. I can only see Cognigram as the only digital disruptor to traditional practices, a niche market they can own.
Lets not forget the formidable list of pharmaceutical clients, the numbers of scientific researches and test records that CGS owns.
CGS Price at posting:
$1.02 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)